GKOS - Glaukos Corporation

NYSE - NYSE Delayed Price. Currency in USD
58.58
-2.58 (-4.22%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close 61.16
Open 60.88
Bid 58.53 x 1400
Ask 58.58 x 1000
Day's Range 58.25 - 60.88
52 Week Range 43.41 - 84.65
Volume 361,987
Avg. Volume 436,542
Market Cap 2.158B
Beta (3Y Monthly) 1.75
PE Ratio (TTM) N/A
EPS (TTM) -0.35
Earnings Date May 4, 2017 - May 5, 2017
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 77.14
Trade prices are not sourced from all markets
  • GKOS Eyes Buy Point
    Investor's Business Daily Video

    GKOS Eyes Buy Point

    Glaukos, which makes stents to treat glaucoma, is working on a 79.23 buy point. Company is losing money, but should turn around in 2020. Earnings are due Aug. 7, so wouldn't offer a lot of time to build a cushion.STOCK MARKET TODAY is sponsored by Interactive Brokers. To open an account, go to ibkr.com/whyib

  • Thomson Reuters StreetEvents

    Edited Transcript of GKOS earnings conference call or presentation 7-Aug-19 8:30pm GMT

    Q2 2019 Glaukos Corp Earnings Call

  • GlobeNewswire

    TRCB, AVDR, CBM, and NCI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

    WILMINGTON, Del., Aug. 13, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Two River Bancorp (NASDAQ GM: TRCB) regarding possible breaches of fiduciary.

  • Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised
    Zacks

    Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised

    Glaukos (GKOS) raises 2019 revenues view; optimistic about Avedro buyout.

  • Avedro and Glaukos Join Forces
    Motley Fool

    Avedro and Glaukos Join Forces

    Glaukos makes a bid for Avedro in an all-stock transaction.

  • GlobeNewswire

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Avedro, Inc. to Glaukos Corporation is Fair to Shareholders

    NEW YORK, Aug. 08, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Avedro, Inc. (“Avedro” or the.

  • Benzinga

    The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 7) Akero Therapeutics Inc (NASDAQ: AKRO ) Allakos Inc (NASDAQ: ...

  • Should You Worry About Glaukos Corporation's (NYSE:GKOS) CEO Pay?
    Simply Wall St.

    Should You Worry About Glaukos Corporation's (NYSE:GKOS) CEO Pay?

    Thomas Burns became the CEO of Glaukos Corporation (NYSE:GKOS) in 2002. This report will, first, examine the CEO...

  • Glaukos (GKOS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Glaukos (GKOS) Q2 2019 Earnings Call Transcript

    GKOS earnings call for the period ending June 30, 2019.

  • Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

    Glaukos (GKOS) delivered earnings and revenue surprises of -10.00% and 4.30%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Glaukos Corporation Announces Second Quarter 2019 Financial Results

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2019.

  • Business Wire

    Glaukos and Avedro Announce Definitive Acquisition Agreement

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, and Avedro, Inc. (AVDR), a leading hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders, today announced that the companies have entered into a definitive merger agreement under which Glaukos will acquire Avedro in an all-stock transaction. The transaction, which is subject to Avedro stockholder approval along with other customary closing conditions and regulatory approvals, has been approved by the board of directors of both companies and is expected to be completed in the fourth quarter of 2019. Glaukos plans to leverage its proven market-building expertise, global commercial scale and extensive clinical and regulatory infrastructure to maximize Avedro’s disruptive bio-activated pharmaceuticals and pipeline.

  • This Biotech Stock Just Broke Out — Is It On The Path To Profitability?
    Investor's Business Daily

    This Biotech Stock Just Broke Out — Is It On The Path To Profitability?

    Glaukos stock broke out Wednesday — a week ahead of what analysts expect to be the biotech company's third straight quarter of double-digit sales gains. Glaukos is set to report Aug. 7.

  • GuruFocus.com

    Interwest Venture Management Co Buys Glaukos Corp

    Investment company Interwest Venture Management Co (Current Portfolio) buys Glaukos Corp during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Interwest Venture Management Co. Continue reading...

  • Business Wire

    Glaukos Announces Global Licensing Agreement With Intratus, Inc.

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Intratus, Inc. under which Intratus has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Intratus’ patented, non-invasive drug delivery platform designed for use in the treatment of dry eye disease, glaucoma and other corneal disorders, such as allergy, blepharitis, conjunctivitis and related conditions.

  • Business Wire

    Glaukos Corporation to Release Second Quarter 2019 Financial Results after Market Close on August 7

    Conference Call and Webcast Scheduled for 1:30 p.m. PDT

  • Have Insiders Been Selling Glaukos Corporation (NYSE:GKOS) Shares?
    Simply Wall St.

    Have Insiders Been Selling Glaukos Corporation (NYSE:GKOS) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Business Wire

    Glaukos Corporation Completes Acquisition of DOSE Medical Corporation

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies, announced today that it has successfully completed the acquisition of DOSE Medical Corporation that was previously announced on June 19, 2019. With the transaction’s completion, DOSE Medical has now become a wholly owned subsidiary of Glaukos. DOSE Medical is developing multiple micro-invasive, bioerodible, sustained-release drug delivery platforms designed to be used in the treatment of various retinal diseases, including age-related macular degeneration and diabetic macular edema.

  • This Is What Hedge Funds Think About Glaukos Corporation (GKOS)
    Insider Monkey

    This Is What Hedge Funds Think About Glaukos Corporation (GKOS)

    Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 40% and 25% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted […]

  • Benzinga

    The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 19) Abbott Laboratories (NYSE: ABT ) CareDx Inc (NASDAQ: ...

  • Business Wire

    Glaukos Corporation Enters into Definitive Agreement to Acquire DOSE Medical Corporation

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical therapies, announced today that it has entered into a definitive Agreement and Plan of Merger to acquire DOSE Medical Corporation (DOSE Medical) for $2.5 million in cash, plus performance-based consideration upon achievement of certain regulatory approvals and commercial milestones. Upon the consummation of the acquisition, DOSE Medical will become a wholly owned subsidiary of Glaukos.

  • Markit

    See what the IHS Markit Score report has to say about Glaukos Corp.

    Glaukos Corp NYSE:GKOSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for GKOS with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 3. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding GKOS are favorable, with net inflows of $1.22 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Has Glaukos Corporation (NYSE:GKOS) Got Enough Cash?
    Simply Wall St.

    Has Glaukos Corporation (NYSE:GKOS) Got Enough Cash?

    Mid-caps stocks, like Glaukos Corporation (NYSE:GKOS) with a market capitalization of US$2.5b, aren’t the focus of...

  • Glaukos (GKOS) Down 2.5% Since Last Earnings Report: Can It Rebound?
    Zacks

    Glaukos (GKOS) Down 2.5% Since Last Earnings Report: Can It Rebound?

    Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.